Education
About Us
Working with TipRanks
Follow Us
Biofrontera (BFRI)
NASDAQ:BFRI
Earnings Data
Report Date
May 08, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.47Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong positive operational and strategic progress: record revenues, a highly profitable Q4 driven by a materially improved cost structure from the acquisition of U.S. assets, clear commercial execution with unit and lamp placement growth, and multiple positive clinical readouts with an imminent PDUFA for sBCC. Key near-term challenges remain — full-year GAAP losses and negative adjusted EBITDA, continued cash burn with modest year-end liquidity, elevated legal costs, and dependence on upcoming regulatory approvals. Management expects the full financial benefit of the new earn-out/cost structure to be realized in 2026, which, combined with the clinical pipeline and financing activity, supports a constructive outlook despite remaining execution and regulatory risks.Company Guidance
Record Revenue Performance
Record full-year revenues of $41.7M, up ~12% YoY, and record Q4 revenue of $17.1M, up ~36% YoY — the highest quarterly revenue in company history.
Quarterly Profitability and Margin Expansion
Q4 2025 adjusted EBITDA of $4.9M and net income of $5.6M (vs. net loss in Q4 2024), with adjusted EBITDA margin improving to +29% from -11% year-over-year.
Substantial Gross Profit Improvement from Strategic Transaction
Related-party COGS declined materially (COGS down ~45% YoY in Q4; full-year related-party COGS down $7.7M or ~43%), driving gross profit on product sales from ~50% to 74% for full-year 2025 and Q4 gross margin improvement to ~82%.
Acquisition of U.S. Commercial and Regulatory Assets
Closed asset purchase from former parent Biofrontera AG acquiring U.S. rights, NDA/IND, manufacturing and patents; new earn-out structure of 12% (≤$65M) / 15% (>$65M) replaces prior 25–35% transfer pricing — materially improving unit economics and gross margins.
Commercial Execution and Volume Growth
Full-year Ameluz unit volume ~121,000 tubes (≈10% volume growth YoY) and Q4 unit volume ~49,840 tubes; installed RhodoLED base ~745 lamps across ~686 dermatology offices with ~85 lamp placements in 2025 (including ~70 XL models).
Clinical and Regulatory Milestones
sBCC Phase III: 76% complete histological clearance vs 19% placebo and 83% clinical clearance vs 21% placebo; FDA accepted supplemental NDA with PDUFA date 09/28/2026. AK extremities Phase III met primary endpoint and sNDA filing planned in 2026. Acne Phase II positive: 58% reduction in inflammatory lesions vs 37% with vehicle; 86% patient satisfaction.
Strengthened IP and Legal Outcomes
Approval for improved Ameluz formulation (propylene glycol removed) extends patent protection through December 2043; PTAB final written decision found challenged Sun Pharma patent claims unpatentable (Sun Pharma may seek review).
Liquidity and Financing Activity
Secured $11M gross proceeds from Series C preferred private placement and $3M initial proceeds from sale of Xepi license (up to $7M additional milestones), contributing to cash and strategic flexibility; cash and cash equivalents of $6.4M as of 12/31/2025.
BFRI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BFRI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 19, 2026 | $0.87 | $0.85 | -1.50% |
Nov 13, 2025 | $0.97 | $0.89 | -8.53% |
Aug 13, 2025 | $0.95 | $0.97 | +1.68% |
May 15, 2025 | $0.70 | $0.65 | -7.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biofrontera (BFRI) report earnings?
Biofrontera (BFRI) is schdueled to report earning on May 08, 2026, Before Open (Confirmed).
What is Biofrontera (BFRI) earnings time?
Biofrontera (BFRI) earnings time is at May 08, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BFRI EPS forecast?
BFRI EPS forecast for the fiscal quarter 2026 (Q1) is -0.12.